This clinical trial will test a drug called A3907 to see how safe and tolerated it is for treating people with primary sclerosing cholangitis (PSC). This clinical trial is currently recruiting volunteers in France, Italy and Spain. The trial will not recruit people from the UK.
For more information, see clinicaltrials.gov NCT05642468 or contact the pharmaceutical company running the trial, Ipsen, at clinical.trials@ipsen.com.
Note, you may see reference to Albireo on clinicaltrials.gov website. This is because Ipsen acquired Albireo in 2023.
TheA3907 study is a Phase II trial. For more information about different types of clinical trial, what's usually involved, and questions to ask, download or order our free Guide to PSC Clinical Trials.
